Prosecution Insights
Last updated: November 18, 2026
Application No. 17/069,726

METHOD FOR INDUCING ANGIOGENESIS

Final Rejection §112
Filed
Oct 13, 2020
Priority
Jan 17, 2014 — provisional 61/928,986 +2 more
Examiner
DAVIS, RUTH A
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mimedx Group Inc.
OA Round
6 (Final)
61%
Grant Probability
Moderate
7-8
OA Rounds
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
560 granted / 919 resolved
+0.9% vs TC avg
Strong +31% interview lift
Without
With
+31.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
44 currently pending
Career history
967
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant's amendment and reply filed May 15, 2026 have been received and entered into the case. Claims 17, 27 - 30, 33 - 38 and 40 - 44 are pending and have been considered on the merits. All arguments have been fully considered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 17, 27 – 30, 33 – 38 and 40 – 44 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 17 (and dependents) recite(s) a method for inducing angiogenesis wherein the method requires a step of extracting placental growth factors from amniotic basement membrane. The specification does not describe this step as originally filed. Rather, the specification teaches extracting growth factors from a placental tissue, specifically a dehydrated human amnion/chorion graft material, which may include a basement membrane. The specification recites “basement membrane” in three occurrences: 1) the amnion is placed basement membrane layer down (0053, PgPubs); 2) the basement membrane is exposed (0056, PgPubs); and 3) the basement membrane is intact post de-epithelialization (0058, PgPubs). However, the specification fails to identify or describe any method step of extracting growth factors from a basement membrane alone as claimed. This is a new mater rejection. Response to Arguments Applicant argues that the specification describes extracting growth factors from amnion basement membrane, citing paragraphs 0094 and 0033, and stating that "it will be understood that obtaining an extract of the amnion will necessarily extract growth factors from all elements of the amnion, including the basement membrane." Applicant additionally argues that while the example extracts growth factors from amnion/chorion membranes, the specification indicates other placental tissues or components thereof can be extracted as well, and that one would understand the amnion is a placental tissue. However, these arguments fail to assert or evidence that the specification as originally filed describes extracting growth factors from the amniotic basement membrane as recited in claim 17. There is no question that the specification describes preparing various placental tissue grafts (e.g., amnion, chorion, Wharton's jelly) by dehydrating, freeze drying, micronizing (0033). Moreover, it is agreed that amnion is a placental tissue. In this regard, it is unclear why applicant emphasizes that one would understand the amnion is placental tissue. It is also agreed that by extracting an amnion, one would necessarily extract growth factors from all elements therein such as the basement membrane, provided that those elements have not been removed prior to extraction. The claimed method recites "extracting placental growth factors from the amniotic basement membrane" which is not described in the specification explicitly or implicitly. Neither of the paragraphs cited by applicant suggest extracting growth factors from an amniotic basement membrane as argued or claimed. Thus, the arguments are not commensurate with the claimed invention. Turning to example 1, extracts from a proprietary dehydrated human amnion/chorion grafts (dHACM) are prepared by extracting a material prepared by a specific method, containing dehydrated amnion and chorion. In this regard, the example does not describe extracting growth factors from amniotic basement membrane, but only from a particular dHACM processed in a specific way (example 1, p.33). Moreover, this is not the same as providing an amnion comprising an amnion basement membrane and extracting growth factors from the amniotic basement membrane. Therefore, the claims remain rejected. No claims are allowed. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUTH A DAVIS whose telephone number is (571)272-0915. The examiner can normally be reached Monday - Friday (8am - 4pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached on 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUTH A DAVIS/ Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Show 15 earlier events
Oct 29, 2025
Request for Continued Examination
Oct 29, 2025
Response after Non-Final Action
Dec 16, 2025
Non-Final Rejection mailed — §112
May 15, 2026
Response Filed
Jul 29, 2026
Final Rejection mailed — §112
Nov 05, 2026
Interview Requested
Nov 17, 2026
Applicant Interview (Telephonic)
Nov 17, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778160
Method and Composition For Reducing Pathogens in Pet Food Using Lactic Acid Bacteria
6y 6m to grant Granted Nov 03, 2026
Patent 12774459
TRUNCATED MODIFIED RECOMBINANT ADAMTS13 AND USES THEREOF
3y 6m to grant Granted Oct 27, 2026
Patent 12773431
COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS
3y 2m to grant Granted Oct 27, 2026
Patent 12766045
Auto-Biodegradable Absorbent Articles
3y 9m to grant Granted Oct 20, 2026
Patent 12766224
DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUE
1y 5m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+31.0%)
High
PTA Risk
Based on 919 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month